论文部分内容阅读
目的探讨雌激素受体（ｅｓｔｒｏｇｅｎｒｅｃｅｐｔｏｒ，ＥＲ）状况对腋淋巴结阴性（以下简称ＮＬ）乳腺癌患者预后的影响。方法对我院１９８５年４月至１９９２年８月手术治疗的１２８例ＮＬ乳腺癌患者和２６６例腋窝淋巴结转移的乳腺癌患者，用免疫组织化学法检测其标本的ＥＲ状况，并对患者进行随访。结果１２８例ＮＬ乳腺癌ＥＲ检测阳性率７１１％，同期腋窝淋巴结转移的乳腺癌２２６例的ＥＲ阳性率为４５５％，二者的差异有非常显著的意义（Ｐ＜００１）。发生转移及复发１９例，ＥＲ阳性和阴性组的复发转移率分别为１２１％和２１６％；５年生存率为９４５％和８３８％（Ｐ＜００５）；１０年生存率为６８２％和６００％（Ｐ＞００５）。１２８例ＮＬ乳腺癌患者中随访１２６例，占９８４％，随访时间６０～１４４个月，平均８０９个月。结论ＮＬ乳腺癌的ＥＲ状况是影响预后的重要因素，ＥＲ阴性组发生复发转移多于阳性组，且易转移至内脏，其５年生存率也明显低于ＥＲ阳性组。故对ＮＬ乳腺癌，当ＥＲ阴性时，应积极施行化学药物治疗在内的辅助治疗以提高疗效
Objective To investigate the effect of estrogen receptor (ER) status on the prognosis of patients with axillary lymph node (NL) breast cancer. Methods 128 cases of NL breast cancer patients and 266 cases of breast cancer patients with axillary lymph node metastasis treated in our hospital from April 1985 to August 1992 were examined for their ER status by immunohistochemistry and the patients were followed up. . Results The positive rate of ER detection in 128 cases of NL breast cancer was 71.1%, and the positive rate of ER in 226 cases of axillary lymph node metastasis was 45.5%. There was a significant difference between the two groups (P<001). . In 19 patients with metastasis and recurrence, the recurrence and metastasis rates of ER positive and negative groups were 12.1% and 21.6%, respectively; the 5-year survival rates were 94.5% and 83.8% (P<0.05); The 10-year survival rate was 682% and 600% (P>005). Among 128 patients with NL breast cancer, 126 patients were followed up, accounting for 98.4%. The follow-up time was 60-144 months, with an average of 80 days and 9 months. Conclusion The ER status of NL breast cancer is an important factor influencing the prognosis. The ER-negative group has more recurrence and metastasis than the positive group, and it is easy to metastasize to the internal organs. The 5-year survival rate is also significantly lower than that of the ER-positive group. Therefore, for NL breast cancer, when ER is negative, adjuvant therapy such as chemical drug therapy should be actively performed to improve efficacy.